Scott Thomas Smith, EVP & Chief Financial Officer at Ascendis Pharma A/S (ASND), bought 100 shares at $219.00 ($22K) on 2026-06-02, disclosed to the SEC on 2026-06-02.
CFO Scott Thomas Smith purchased 100 shares for $21,900, marking the largest purchase of his career, signaling confidence in the company's commercial momentum. This rare insider buying comes as the stock trades near its 52-week low, potentially offering a value entry point.
The stock is down 9.69% over the last 5 days and 2.06% over the last 30 days, trading 13.74% below its 52-week high of $250.74 and just 1.51% above its 52-week low of $213.06.
1) Q2 2026 earnings on August 13, 2026, where product revenue more than doubled year-over-year; 2) Continued regulatory review of YUVIWEL in Europe; 3) The company's largest-ever insider purchase on June 2, 2026, indicating strong conviction.
1) A recent analyst note from Artisan Small Cap Fund on July 24, 2026, cited lawsuit concerns as a reason to trim positions; 2) The stock is trading 24.0% higher over the past 30 days, which raises the bar for future fundamental delivery.
Something here stands out, but not much.